Trials / Completed
CompletedNCT06255665
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
A Phase 1 Study of JNJ-79032421, a T-cell Redirecting Agent Targeting Mesothelin for Advanced Stage Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-79032421 and to determine the safety and tolerability of JNJ-79032421 at the RP2D(s).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-79032421 | JNJ-79032421 will be administered. |
| DRUG | JNJ-79032421 | JNJ-79032421 will be administered at RP2D regimen. |
Timeline
- Start date
- 2024-02-09
- Primary completion
- 2025-06-23
- Completion
- 2025-06-23
- First posted
- 2024-02-13
- Last updated
- 2025-07-20
Locations
3 sites across 1 country: Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06255665. Inclusion in this directory is not an endorsement.